Radioimmunotherapy of human colon cancer xenografts by using {sup 131}I labeled-CAb{sub 1} F(ab'){sub 2}
- Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, Fourth Military Medical University, Xi'an (China)
- Cell Engineering Research Centre and Department of Cell Biology, State Key Laboratory of Cancer Biology, the Fourth Military Medical University, Xi'an (China)
- Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an (China)
Purpose: Therapeutic efficacy, suitable dose, and administration times of {sup 131}I-CAb{sub 1} F(ab'){sub 2}, a new monoclonal antibody therapeutics specifically directed against a cell surface-associated glycoprotein of colon cancer, were investigated in this article. Methods and Materials: In human colon cancer xenografts, {sup 131}I-CAb{sub 1} F(ab'){sub 2} at the dose of 125 {mu}Ci, 375 {mu}Ci, and 1125 {mu}Ci were administrated intraperitoneally on Days 6 and 18 after implantation of HR8348 cells with CAb{sub 1} high reactivity. Survival time and tumor growth inhibition rate were used to evaluate the efficacy and safety of {sup 131}I-CAb{sub 1} F(ab'){sub 2} in treatment of colon cancer xenografts. Results: Treatment of 125, 375, and 1125 {mu}Ci {sup 131}I-CAb1 F(ab'){sub 2} did not significantly decrease the mean survival time of nude mice when compared with nontreated groups (p = 0.276, 0.865, 0.582, respectively). Moreover, the mean survival times of nude mice receiving 375 {mu}Ci and 1125 {mu}Ci {sup 131}I-CAb1 F(ab'){sub 2} were significantly longer than that of 5-FU-treated groups (p 0.018 and 0.042). Tumor growth inhibition rates of the first therapy were 35.67% and 41.37%, with corresponding {sup 131}I-labeled antibody dosage of 375 {mu}Ci and 1125 {mu}Ci. After single attack dosage, second reinforcement therapy may rise efficacy significantly. Tumor growth inhibition rates of 125 {mu}Ci, 375 {mu}Ci, and 1125 {mu}Ci {sup 131}I-labeled antibody on Day 20 posttherapy were 42.65%, 56.56%, and 84.41%, respectively. Histopathology examination revealed that tissue necrosis of various degrees was found in {sup 131}I-CAb1 F(ab'){sub 2}-treated groups. Conclusion: {sup 131}I-CAb{sub 1} F(ab'){sub 2} is safe and effective for colon cancer. It may be a novel and potentially adjuvant therapeutics for colon cancer.
- OSTI ID:
- 20850244
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 66, Issue 4; Other Information: DOI: 10.1016/j.ijrobp.2006.04.050; PII: S0360-3016(06)00859-5; Copyright (c) 2006 Elsevier Science B.V., Amsterdam, Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Pharmacokinetics of /sup 99m/Tc(Sn)- and /sup 131/I-labeled anti-carcinoembryonic antigen monoclonal antibody fragments in nude mice
Use of second antibody in radioimmunotherapy